Detection of egfr mutations and eml4-alk rearrangements in lung adenocarcinomas using archived cytological slides

Cancer Cytopathology

Volumn 121, Issue 7, 2013, Pages 370-376

  Mitiushkina, Natalia V ^a   Iyevleva, Aglaya G ^a,b   Poltoratskiy, Artiom N ^c   Ivantsov, Alexandr O ^a   Togo, Alexandr V ^a   Polyakov, Igor S ^d   Orlov, Sergey V ^c   Matsko, Dmitry E ^a   Novik, Viktor I ^a   Imyanitov, Evgeny N ^a,b,e  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^d KUBAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^e NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

Author keywords

Anaplastic lymphoma kinase (alk); Cytological analysis; Epidermal growth factor receptor (egfr); Lung cancer; Russia

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CELL; CYTOLOGY; DNA ISOLATION; EGFR GENE; EML4 ALK; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE FUSION; GENE REARRANGEMENT; GENE TRANSLOCATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA ISOLATION; ADENOCARCINOMA; ANAPLASTIC LYMPHOMA KINASE (ALK); CYTODIAGNOSIS; CYTOLOGICAL ANALYSIS; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; LUNG CANCER; LUNG TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; RUSSIAN FEDERATION;

DNA; EGFR PROTEIN, HUMAN; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; ONCOPROTEIN; PARAFFIN; RNA;

ANAPLASTIC LYMPHOMA KINASE (ALK); CYTOLOGICAL ANALYSIS; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); LUNG CANCER; RUSSIA;

ADENOCARCINOMA; AGED; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE REARRANGEMENT; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ONCOGENE PROTEINS, FUSION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; RNA, NEOPLASM; TRANSLOCATION, GENETIC;

EID: 84884762470     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21281     Document Type: Article

References (42)

1. Burton A. What went wrong with Iressa? Lancet Oncol. 2002;3:708. (Pubitemid 35446721)
2. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306-13311. (Pubitemid 39209661)
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129- 2139. (Pubitemid 38637993)
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: 947-957.
6. Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall- cell lung cancer: A meta-analysis of 13 randomized trials. Clin Lung Cancer. 2012;13:107-114.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
8. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010;18:548-551.
9. Pirker R, Herth FJ, Kerr KM, et al; European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5:1706-1713.
10. Pang B, Matthias D, Ong CW, et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases. Cytopathology. 2012;23:229-236.
11. Ma ES, Ng WK, Wong CL. EGFR gene mutation study in cytology specimens. Acta Cytol. 2012;56:661-668.
12. Hagiwara K, Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer [published online ahead of print December 13, 2012]. Cancer Sci. doi: 10.1111/cas.12081.
13. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: A review. Diagn Cytopathol. 2011;39:703-710.
14. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer (Cancer Cytopathol). 2011;119: 80-91.
15. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: an institutional experience [published online ahead of print November 18, 2011]. Diagn Cytopathol. doi: 10.1002/dc.21851.
16. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136:564-571.
17. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer (Cancer Cytopathol). 2011;119: 111-117.
18. Bruno P, Mariotta S, Ricci A, et al. Reliability of direct sequencing of EGFR: comparison between cytological and histological samples from the same patient. Anticancer Res. 2011;31:4207- 4210.
19. Hlinkova K, Babal P, Berzinec P, Majer I, Ilencikova D. Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis. Mol Diagn Ther. 2011;15:21-29.
20. Marotti JD, Schwab MC, McNulty NJ, et al. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: A retrospective review of 50 cases. Diagn Cytopathol. 2013;41:15-21.
21. Santis G, Angell R, Nickless G, et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLDPCR. PLoS One. 2011;6:e25191.
22. Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytologicalstained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist. 2011;16:877-885.
23. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6:451-458.
24. Shingyoji M, Kageyama H, Sakaida T, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol. 2011;6:1215-1220.
25. van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 2011;6:e17791.
26. Bozzetti C, Negri FV, Azzoni C, et al. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. Diagn Cytopathol. 2013;41:595-598.
27. Malapelle U, de Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: A pilot study. J Clin Pathol. 2013;41:595-598.
28. Malapelle U, de Rosa N, Bellevicine C, et al. EGFR mutations detection on liquid-based cytology: is microscopy still necessary? J Clin Pathol. 2012;65:561-564.
29. Allegrini S, Antona J, Mezzapelle R, et al. Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. Am J Clin Pathol. 2012;138:377-381.
30. Sun PL, Jin Y, Kim H, Lee CT, Jheon S, Chung JH. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer (Cancer Cytopathol). 2013;121:311-319.
31. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006;126:608-615. (Pubitemid 44498512)
32. Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012;25:347-369.
33. Moiseyenko VM, Procenko SA, Levchenko EV, et al. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie. 2010;33:231-238.
34. Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012;118:729-739.
35. Iyevleva AG, Buslov KG, Togo AV, et al. Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees. Onkologie. 2007;30:295-300. (Pubitemid 46878910)
36. Horn L, Pao W. EML4-ALK: honing in on a new target in nonsmall- cell lung cancer. J Clin Oncol. 2009;27:4232-4235.
37. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010;16:4938-4945.
38. Kanaji N, Bandoh S, Ishii T, et al. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy. Lung Cancer. 2012;77:293-298.
39. Yi ES, Chung JH, Kulig K, Kerr KM. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: A literature review. Mol Diagn Ther. 2012;16:143-150.
40. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 50 and 30 portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012;18:4725-4732.
41. Chen ZY, Zhong WZ, Zhang XC, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012;17:978-985.
42. Milbury CA, Correll M, Quackenbush J, Rubio R, Makrigiorgos GM. COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. Clin Chem. 2012;58:580-589.